Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancers
Carole Sourbier(Center for Drug Evaluation and Research), W. Marston Linehan(Massachusetts General Hospital)
Cited by 57
Related Papers
Recent Advances in Targeting ROS1 in Lung Cancer
|Journal of Thoracic Oncology|2017|259
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
|npj Precision Oncology|2020|65